The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?
View/ Open
Published version
Embargoed until: 5555-01-01
Reason: Version Not Permitted
Embargoed until: 5555-01-01
Reason: Version Not Permitted
Volume
4
Pagination
3 - 5
DOI
10.1016/j.msard.2014.11.005
Journal
Multiple Sclerosis and Related Disorders
Issue
ISSN
2211-0348
Metadata
Show full item recordAbstract
©2014 Elsevier B.V. All rights reserved. If it is not feasible to develop licensed drugs to the stage that they can actually be prescribed for a new indication, can we justify, either ethically or economically, the undertaking of proof-of-concept studies using off-patent medications? Without a financial incentive it is very difficult to repurpose off patent drugs for a new indication. Therefore, we need a political solution to allow the repurposing of off-patent drugs by other stakeholders or Big Pharma.
Authors
Giovannoni, G; Baker, D; Schmierer, KCollections
- Centre for Immunobiology [1100]